Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
Study Details
Study Description
Brief Summary
This is for subjects with metastatic Renal Cell Cancer (RCC). There are four Food and Drug Administration (FDA) approved drugs for first-line therapy of Renal Cell Cancer (RCC) and two for second-line therapy. Each of these drugs targets a specific molecular pathway. At present oncologists select therapy based on current guidelines. There is a new method for trying to use biomarker information from the subject's tumor to select the best drug to treat the subject. This process is investigational, which is why this study is being done.
Biomarkers are genes, proteins and other molecules that affect how cancer cells grow, multiply, die and respond to other compounds in the body. These biomarkers build a tumor profile or "fingerprint" of the subject's tumor. A new focus in cancer care is personalized treatment, where doctors select a drug based on the subject's tumor's unique "fingerprint" which is more likely to be effective in fighting the tumor. Selecting the treatment the subject is more likely to respond to requires a thorough understanding of the relationship between biomarker and treatment effect. The PI wants to gather data to understand that relationship to help treat future cancer patients. The purpose of this study is to evaluate efficacy of treatments that are selected based on tumor profiles.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2 |
Detailed Description
This will be a prospective, one-arm, proof of concept study designed to evaluate the efficacy of algorithm-based allocation (based on genomic/proteomic profile) of first-line therapy in renal cell carcinoma (RCC).
After eligibility review, patients will receive one of the four first-line therapy agents based on their tumor's molecular profile as determined using fresh biopsy tissue from an accessible metastatic site. Upon disease progression, patients will then receive one of two second-line agents based on their tumor's molecular profile.
Because this is a proof-of-concept study, the sample size is based on feasibility of accrual. The clinic should be able to recruit 100 patients within a reasonable timeframe for the study. The number of patients receiving each drug will vary based on the frequency of molecular alterations in the population. Therefore, groups will not be compared with one another - the research goal is to determine whether the progression-free survival (PFS) for each drug is improved over the PFS reported in FDA approval trials for each drug when they are assigned based on molecular analysis.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Other: Personalized therapy Subjects will receive one of the four first-line therapy agents based on their tumor's profile. The first-line agents are sunitinib, temsirolimus, sorafenib, or pazopanib. These are all routine drugs for RCC treatment and will be given at their approved doses and dosing schedules. Upon disease progression, subject's tumor(s) will be biopsied again to create another tumor profile. The second-line agents are everolimus or axitinib. Both of these are routine drugs for RCC treatment and will be given at their approved doses and dosing schedules. |
Drug: Sunitinib
One 50-mg capsule taken orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off
Other Names:
Drug: Temsirolimus
25 mg by an IV infusion over 30-60 minutes, once a week
Other Names:
Drug: Sorafenib
400 mg (2 tablets) orally twice daily without food
Other Names:
Drug: Pazopanib
800 mg orally once a day without food, at least 1 hour before or 2 hours after a meal
Other Names:
Drug: Everolimus
10 mg orally once daily with or without food
Other Names:
Drug: Axitinib
5 mg orally twice daily
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Number of Participants Who Progressed [From date of enrollment until the date of first documented progression, date of death from any cause, or date that the study was stopped, whichever came first, an average of 16 months]
The PFS is defined as the time elapsed between treatment initiation and tumor progression or death from any cause, with censoring of patients who are lost to follow-up. Progression is defined using the Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1): " At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression)."
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Subjects may be included in the study only if they meet all of the following inclusion criteria:
-
Pathologically confirmed renal cell carcinoma.
-
No prior systemic and/or investigative therapy of any kind.
-
Patients with primary tumor in place are strongly encouraged to undergo nephrectomy prior to initiation of study agent.
-
Prior palliative radiotherapy to metastatic lesion(s) is permitted. Patient must have adequately recovered from the acute toxicities of this treatment.
-
All major surgery of any type and/or radiotherapy must be completed at least 4 weeks prior to registration.
-
Must have progressive metastatic disease
-
ECOG performance status ≤2
-
Women of childbearing potential and male patients must use acceptable methods of contraception-tubal ligation, vasectomy, barrier contraceptive with spermicide-while on study and for 3 months after the last dose of study therapy. Oral, implantable, or injectable contraceptives may be affected by cytochrome P450 interactions, and are therefore not considered effective for this study.
-
Age ≥18 years
-
Required Initial Laboratory Values:
-
Granulocytes ≥1,500/µL
-
Platelet Count ≥100,000/µL
-
Hemoglobin ≥9 g/dL
-
AST/ALT ≤ 2.5 times the upper limit of normal (ULN)
-
Alk. Phos.≤ 2.5 x ULN
-
Serum bilirubin ≤ 1.5 x ULN
-
Amylase/Lipase within normal range
-
Urinalysis≤ 1+ protein
-
T3T4 TSH - within normal range
-
Pregnancy test for women - Negative
-
Serum creatinine ≤ 1.5 x ULN
-
Electrocardiogram (ECG) - no active ischemia
-
Echocardiogram ejection fraction ≥40%
-
Pulmonary function tests
-
Fasting serum cholesterol ≤300 mg/dL OR ≤7.75 mmol/L AND fasting triglycerides ≤2.5 x ULN. NOTE: In case one or both of these thresholds are exceeded, the patient can only be included after initiation of appropriate lipid lowering medication.
-
Signed informed consent prior to the performance of any study-specific procedures
Exclusion Criteria:
-
Ongoing hemoptysis, or cerebrovascular accident within 12 months prior to study entry, or peripheral vascular disease with claudication occurring upon walking less than one city block, or history of clinically significant bleeding.
-
Deep venous thrombosis or pulmonary embolus within 12 months prior to study entry and no ongoing need for full-dose oral or parenteral anticoagulation. For maintenance of catheter patency daily prophylactic aspirin or low-dose coumadin (1-2 mg) is allowed.
-
Evidence of current central nervous system (CNS) metastases. All patients must undergo a CT scan of the brain (with contrast, if possible) within 42 days prior to registration. Any imaging abnormality indicative of active CNS metastases will exclude the patient from the study.
-
Significant cardiovascular disease defined as congestive heart failure (New York Heart Association Class II, II or IV) angina pectoris requiring nitrate therapy, or recent myocardial infarction (within the preceding 6 months prior to study entry).
-
Uncontrolled hypertension (defined as blood pressure of ≥160 mmHg systolic and/or ≥90 mmHg diastolic on medication). Document over 48 hours with minimum of 3 readings.
-
Ongoing requirement for systemic corticosteroid therapy (except replacement therapy for adrenal insufficiency) or other immunosuppressants are not permitted. Topical and/or inhaled steroids are allowed.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | UTHealth Memorial Hermann Cancer Center | Houston | Texas | United States | 77030 |
Sponsors and Collaborators
- The University of Texas Health Science Center, Houston
Investigators
- Principal Investigator: Robert Amato, DO, The University of Texas Health Science Center, Houston
Study Documents (Full-Text)
More Information
Publications
None provided.- GU-14-102
- HSC-14-0665
Study Results
Participant Flow
| Recruitment Details | |
|---|---|
| Pre-assignment Detail | One enrolled patient's tumor did not have a genomic profile completed as next-generation sequencing was not done. Both proteomics and genomics assessments were required so patient was excluded. |
| Arm/Group Title | Personalized Therapy |
|---|---|
| Arm/Group Description | Participants will receive one of four first-line therapy agents based on their tumor's profile. First-line agents are sunitinib, temsirolimus, sorafenib, or pazopanib. These are all routine drugs for RCC treatment and will be given at their approved doses and dosing schedules. Upon disease progression, participant's tumor will be biopsied again to create another tumor profile. The second-line agents are everolimus or axitinib. Both of these are routine drugs for RCC treatment and will be given at their approved doses and dosing schedules. Sunitinib: One 50-mg capsule taken orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off Temsirolimus: 25 mg by an IV infusion over 30-60 minutes, once a week Sorafenib: 400 mg (2 tablets) orally twice daily without food Pazopanib: 800 mg orally once a day without food, at least 1 hour before or 2 hours after a meal Everolimus: 10 mg orally once daily with or without food Axitinib: 5 mg orally twice |
| Period Title: Overall Study | |
| STARTED | 3 |
| COMPLETED | 1 |
| NOT COMPLETED | 2 |
Baseline Characteristics
| Arm/Group Title | Personalized Therapy |
|---|---|
| Arm/Group Description | Participants will receive one of four first-line therapy agents based on their tumor's profile. First-line agents are sunitinib, temsirolimus, sorafenib, or pazopanib. These are all routine drugs for RCC treatment and will be given at their approved doses and dosing schedules. Upon disease progression, participant's tumor will be biopsied again to create another tumor profile. The second-line agents are everolimus or axitinib. Both of these are routine drugs for RCC treatment and will be given at their approved doses and dosing schedules. Sunitinib: One 50-mg capsule taken orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off Temsirolimus: 25 mg by an IV infusion over 30-60 minutes, once a week Sorafenib: 400 mg (2 tablets) orally twice daily without food Pazopanib: 800 mg orally once a day without food, at least 1 hour before or 2 hours after a meal Everolimus: 10 mg orally once daily with or without food Axitinib: 5 mg orally twice |
| Overall Participants | 3 |
| Age (years) [Median (Full Range) ] | |
| Median (Full Range) [years] |
65
|
| Sex: Female, Male (Count of Participants) | |
| Female |
2
66.7%
|
| Male |
1
33.3%
|
| Race/Ethnicity, Customized (Count of Participants) | |
| White |
3
100%
|
| Region of Enrollment (Count of Participants) | |
| United States |
3
100%
|
| Eastern Cooperative Oncology Group Performance Status (ECOG) (Count of Participants) | |
| 0-Fully active, pre-disease performance |
3
100%
|
| 1-No strenuous activity, ambulatory, light work |
0
0%
|
| 2-Ambulatory, selfcare, unable to work |
0
0%
|
| 3-Limited selfcare, confined to bed/chair > 50% |
0
0%
|
| 4-Completely disabled, no selfcare, bed/chair 100% |
0
0%
|
| 5-Dead |
0
0%
|
Outcome Measures
| Title | Number of Participants Who Progressed |
|---|---|
| Description | The PFS is defined as the time elapsed between treatment initiation and tumor progression or death from any cause, with censoring of patients who are lost to follow-up. Progression is defined using the Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1): " At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression)." |
| Time Frame | From date of enrollment until the date of first documented progression, date of death from any cause, or date that the study was stopped, whichever came first, an average of 16 months |
Outcome Measure Data
| Analysis Population Description |
|---|
| All participants who received personalized therapy (sunitinib, temsirolimus, sorafenib, or pazopanib) based on their tumor's profile. |
| Arm/Group Title | Personalized Therapy |
|---|---|
| Arm/Group Description | Participants will receive one of four first-line therapy agents based on their tumor's profile. First-line agents are sunitinib, temsirolimus, sorafenib, or pazopanib. These are all routine drugs for RCC treatment and will be given at their approved doses and dosing schedules. Upon disease progression, participant's tumor will be biopsied again to create another tumor profile. The second-line agents are everolimus or axitinib. Both of these are routine drugs for RCC treatment and will be given at their approved doses and dosing schedules. Sunitinib: One 50-mg capsule taken orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off Temsirolimus: 25 mg by an IV infusion over 30-60 minutes, once a week Sorafenib: 400 mg (2 tablets) orally twice daily without food Pazopanib: 800 mg orally once a day without food, at least 1 hour before or 2 hours after a meal Everolimus: 10 mg orally once daily with or without food Axitinib: 5 mg orally twice |
| Measure Participants | 3 |
| Count of Participants [Participants] |
0
0%
|
Adverse Events
| Time Frame | From the time the participant signs the informed consent until the study was stopped, an average of 16 months | |
|---|---|---|
| Adverse Event Reporting Description | ||
| Arm/Group Title | Personalized Therapy | |
| Arm/Group Description | Participants will receive one of four first-line therapy agents based on their tumor's profile. First-line agents are sunitinib, temsirolimus, sorafenib, or pazopanib. These are all routine drugs for RCC treatment and will be given at their approved doses and dosing schedules. Upon disease progression, participant's tumor will be biopsied again to create another tumor profile. The second-line agents are everolimus or axitinib. Both of these are routine drugs for RCC treatment and will be given at their approved doses and dosing schedules. Sunitinib: One 50-mg capsule taken orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off Temsirolimus: 25 mg by an IV infusion over 30-60 minutes, once a week Sorafenib: 400 mg (2 tablets) orally twice daily without food Pazopanib: 800 mg orally once a day without food, at least 1 hour before or 2 hours after a meal Everolimus: 10 mg orally once daily with or without food Axitinib: 5 mg orally twice | |
All Cause Mortality |
||
| Personalized Therapy | ||
| Affected / at Risk (%) | # Events | |
| Total | 0/3 (0%) | |
Serious Adverse Events |
||
| Personalized Therapy | ||
| Affected / at Risk (%) | # Events | |
| Total | 0/3 (0%) | |
Other (Not Including Serious) Adverse Events |
||
| Personalized Therapy | ||
| Affected / at Risk (%) | # Events | |
| Total | 3/3 (100%) | |
| Blood and lymphatic system disorders | ||
| Anemia | 1/3 (33.3%) | 1 |
| Gastrointestinal disorders | ||
| Abdominal pain | 1/3 (33.3%) | 1 |
| Bloating | 1/3 (33.3%) | 2 |
| Constipation | 1/3 (33.3%) | 2 |
| Diarrhea | 1/3 (33.3%) | 3 |
| Dyspepsia | 1/3 (33.3%) | 2 |
| Gastrointestinal disorders-other, black stool | 1/3 (33.3%) | 1 |
| Mucositis oral | 2/3 (66.7%) | 2 |
| Nausea | 2/3 (66.7%) | 6 |
| Oral dysesthesia | 1/3 (33.3%) | 1 |
| Vomiting | 1/3 (33.3%) | 2 |
| General disorders | ||
| Edema limbs | 1/3 (33.3%) | 3 |
| Fatigue | 2/3 (66.7%) | 3 |
| Fever | 2/3 (66.7%) | 3 |
| Generalized edema | 1/3 (33.3%) | 1 |
| Non-cardiac chest pain | 1/3 (33.3%) | 1 |
| Immune system disorders | ||
| Anaphylaxis | 1/3 (33.3%) | 1 |
| Infections and infestations | ||
| Bronchial infection | 1/3 (33.3%) | 1 |
| Herpes simplex reactivation | 1/3 (33.3%) | 1 |
| Papulopustular | 1/3 (33.3%) | 1 |
| Rash pustular | 1/3 (33.3%) | 2 |
| Investigations | ||
| Creatinine increased | 2/3 (66.7%) | 2 |
| Metabolism and nutrition disorders | ||
| Hyponatremia | 1/3 (33.3%) | 1 |
| Musculoskeletal and connective tissue disorders | ||
| Back pain | 2/3 (66.7%) | 2 |
| Bone pain | 1/3 (33.3%) | 1 |
| Flank pain | 1/3 (33.3%) | 1 |
| Musculoskeletal and connective tissue disorders-other, body aches | 1/3 (33.3%) | 1 |
| Pain in extremity | 1/3 (33.3%) | 1 |
| Nervous system disorders | ||
| Dysgeusia | 1/3 (33.3%) | 1 |
| Headache | 1/3 (33.3%) | 1 |
| Peripheral sensory neuropathy | 1/3 (33.3%) | 1 |
| Psychiatric disorders | ||
| Insomnia | 1/3 (33.3%) | 1 |
| Renal and urinary disorders | ||
| Proteinuria | 1/3 (33.3%) | 1 |
| Urinary tract obstruction | 1/3 (33.3%) | 1 |
| Respiratory, thoracic and mediastinal disorders | ||
| Cough | 1/3 (33.3%) | 1 |
| Dyspnea | 1/3 (33.3%) | 1 |
| Sore throat | 2/3 (66.7%) | 3 |
| Skin and subcutaneous tissue disorders | ||
| Bullous dermatitis | 1/3 (33.3%) | 1 |
| Rash acneiform | 1/3 (33.3%) | 2 |
| Rash maculopapular | 2/3 (66.7%) | 2 |
| Vascular disorders | ||
| Hotflashes | 2/3 (66.7%) | 2 |
| Hypertension | 2/3 (66.7%) | 3 |
Limitations/Caveats
More Information
Certain Agreements
All Principal Investigators ARE employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
| Name/Title | Research Manager |
|---|---|
| Organization | The University of Texas Health Science Center, Houston |
| Phone | 713-500-6919 |
| Marka.Lyons@uth.tmc.edu |
- GU-14-102
- HSC-14-0665